- In February 2023, Julphar launched a new range of pleural anti-inflammatory drugs in Gulf countries to address region-specific pulmonary disease patterns.
- In May 2022, a partnership between Medpharm and a leading Egyptian pharma manufacturer led to the introduction of nano-formulated corticosteroid therapies for mass market distribution.
- In 2024, the UAE Ministry of Health introduced an AI-integrated tele-pulmonology platform to facilitate rapid diagnosis and e-prescription of pleural effusion therapies.
- The report also emphasized the growing importance of green chemistry, continuous manufacturing technologies, and regional self-reliance in reducing supply disruptions. Increased industry focus on API traceability and quality assurance is driving a shift toward more sustainable and transparent production practices in pulmonary therapeutics.
